Aprea Therapeutics Q4 net loss narrows as R&D costs fall
Overview
Oncology drug developer's Q4 net loss narrowed from prior year
Q4 R&D expenses fell due to lower clinical trial costs and fewer personnel expenses
Outlook
Company expects cash and equivalents to fund operations into Q1 2027
Result Drivers
LOWER R&D EXPENSES - Decrease in R&D costs attributed to reduced expenses for ACESOT-1051 and paused ABOYA-119 trials, as well as lower personnel costs
Company press release: ID:nGNXbzpYMG
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS |
| -$0.32 |
|
Q4 Net Income |
| -$2.50 mln |
|
Q4 Operating Income |
| -$2.60 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Aprea Therapeutics Inc is $5.00, about 579.3% above its March 13 closing price of $0.74
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
